IL17A and systemic lupus erythematosus: In line with this, targeting specific cytokines or the activation of specific immune cells by anti-inflammatory therapy (e.g., monoclonal antibodies) lowered cardiovascular mortality in patients with psoriasis (interleukins IL-17/IL-23 axis) [68,69,70], systemic lupus erythematosus (IL-17A signaling) [71], and rheumatoid arthritis (cytokine IL-6, TNF-α, and IL-17A cascades) [72,73].